Obagi Medical Partners with Schweiger Dermatology to Gather Real-World Data for New Injectable saypha® MagIQ™
WALD sits 17% above its 52-week low of $1.45.
Summary
Obagi Medical, a brand under Waldencast plc, has announced a strategic collaboration with Schweiger Dermatology, a leading national dermatology practice. This partnership, part of the ALOHA Program, aims to generate crucial real-world evidence for Obagi® saypha® MagIQ™, a new hyaluronic acid injectable. The program includes a Phase 4 clinical study and a real-world evaluation across Schweiger's extensive network. For a company of Waldencast's size, this collaboration is material as it provides a robust platform for validating and driving adoption of a key new aesthetic product. The generation of real-world data is vital for market acceptance and future sales growth, with initial findings expected to be presented at industry conferences, offering potential future catalysts.
At the time of this announcement, WALD was trading at $1.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $218.3M. The 52-week trading range was $1.45 to $3.54. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.